Dr Nick Ede | Head of Corporate Development

Dr Nick Ede has over 30 years’ peptide vaccine and drug development experience. He was formerly CEO of globally recognised peptide and drug development service company Mimotopes Pty Ltd. Prior to that he was VP Chemistry at Chiron Corp (now Novartis) heading medicinal and combinatorial chemistry programs, and was a Research Fellow with the CRC for Vaccine Technology pioneering infectious disease and cancer peptide vaccines. 

Dr Bradley Glover | Chief Operating Officer

Dr. Glover has over 20 years’ experience across the research, diagnostic and biotechnology industries.  Most recently, he was the Chief Operating Officer at Celularity where he had broad responsibility across multiple business divisions.  Prior to this, he held several executive roles at Kite Pharma in Corporate Development and Technical Operations and was responsible for the strategic oversight and leadership of corporate strategy, corporate program and portfolio management, technical operations strategy, CMC program management and business operations.  He has also held several leadership roles at Genentech, Roche and Illumina in the areas of finance, strategy, supply chain operations, commercial planning, business development and alliance management.  Brad holds a BS degree in biochemistry from the University of California San Diego, a PhD from the University of Colorado in biochemistry and molecular genetics and an MBA from the Rady School of Management at UCSD.  He was also a Jane Coffin Childs Medical Research Fellow at the University of California Berkeley.

Ursula McCurry | Senior Vice President of Clinical Operations

Ursula is a seasoned clinical operations leader with over 20 years of global clinical development experience across a number of established and emerging biotech and pharmaceutical companies including Genentech, Exelixis, Astex, QLT Inc and Amunix.  She has led global clinical operations programs spanning a variety of therapeutic areas and all phases of clinical development, contributing to over 20 programs and subsequent multiple regulatory approvals at both small and large biotech companies. She also brings significant partnership and alliance management experience. Prior to joining Imugene, Ursula served as the VP of Clinical Operations at Amunix Pharmaceuticals and prior to that was a Clinical Program Director at Genentech, leading multiple programs from entry into the clinic to phase three development, including taselisib and GDC-9545. She has also led the Drug Safety teams, ensuring quality, compliance, pharmacovigilance, and safety reporting. Ursula received a Master of Arts degree from Simon Fraser University and a certificate in Biotechnology, Clinical Trial Design and Management from San Francisco State University.

Dr Paul Woodard | Chief Medical Officer

Dr. Woodard worked on a wide range of drug development projects in solid tumors, hematologic malignancies, and non-malignant hematologic disorders. At Exelixis, Dr. Woodard worked on small molecule tyrosine kinase inhibitors for solid tumors. At Amgen, Dr. Woodard was the global development leader for Nplate® (romiplostim) in immune thrombocytopenia and myelodysplastic syndromes. At Genentech, Dr. Woodard was the global development team leader for Tecentriq® (atezolizumab) in hematologic malignancies and was an integral team member for the development of Tecentriq® combinations in solid tumors (including triple negative breast cancer) and hematologic malignancies. At Bellicum, Dr. Woodard was the Senior Vice President of Clinical and Medical Affairs, with oversight of the company’s cellular therapy portfolio and clinical trials in hematologic malignancies and solid tumors. As CMO at Immune-Onc, Dr. Woodard led development of novel myeloid checkpoint inhibitors in the U.S. and China in leukemias and solid tumors.

Monil Shah | Chief Business Officer

Dr. Shah has over 20 years of pharmaceutical and biotechnology industry experience in oncology drug development. His most recent appointment was as Chief Development Officer at WindMIL Therapeutics, responsible for the MILs cell therapy platform. He was the Chief Operating Officer of IRX Therapeutics /Brooklyn ImmunoTherapeutics leading cytokine drug development for oncology patients. Prior to that, he was the Medical Affairs Lead for Immuno-Oncology at Bristol Myers Squibb responsible for checkpoint inhibitor development programs. Dr. Shah also was the Founder and Head of Clinical Development and Operations at Ventrus Biosciences prior to its merger with Assembly Biosciences. Prior to Ventrus, Dr. Shah led the solid tumor development programs and the Clinical Portfolio and Strategic Planning function at Celgene, as well as the Oncology Development and Operations activities at Fibrogen and Novacea. He began his career at Novartis in the Oncology Early Development Group prior to joining the Medical Sciences Group at Amgen. Dr. Shah received his Bachelor of Science in Pharmacy and Doctorate of Pharmacy degrees from Rutgers University in New Jersey.

Mike Tonroe | Chief Financial Officer

Mr Tonroe has extensive experience as a CFO and Company Secretary within the biopharmaceutical industry and also brings international finance leadership experience having worked in the US, Canada, UK and Hong Kong, in addition to Australia. Most recently, Mr Tonroe was CFO and Company Secretary at ASX and NASDAQ-listed Genetic Technologies Limited and Opthea Limited, and prior to that was in the same role for private business Australian Synchotron Company Ltd. These tenures included management of the US IPO and NASDAQ listing of Opthea along with M&A, restructuring, capital raising and leading the finance function across these businesses.

John Byon | Senior VP Clinical Development

Dr. Byon has extensive oncology drug development experience in the pharmaceutical and biotechnology industry. At Genentech, he worked on TecentriqÆ (atezolizumab) in hematological malignancies. For over the past 5 years, he has worked in the cell therapy space. First at Juno as the Global Development Lead for orvacabtagene autoleucel (JCARH-125) in Multiple Myeloma. Then at Lyell, working on next generation cell therapy products for solid tumors. Most recently, he was VP, Clinical Development Hematology at Fate Therapeutics, where he oversaw a portfolio of 5 iPSC-derived cell therapies (CAR-NK and CAR-T) in a various hematologic malignancies (AML, MM, B-cell Lymphoma).